ReviewFrontiers in pharmacology2017

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.

Hashem O Alsaab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.